Nicorandil - Review of pharmacological properties and clinical applications

HeartDrug

Volumn 5, Issue 4, 2005, Pages 220-229

  Schmid, Jean Paul ^a   Schroeder, Verena ^a  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angina pectoris; Heart failure; Ischemic heart disease; Ischemic preconditioning; Nicorandil

Indexed keywords

NICORANDIL; POTASSIUM CHANNEL; SILDENAFIL; TADALAFIL; VARDENAFIL;

ACUTE HEART INFARCTION; ANGINA PECTORIS; CELL PROTECTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; DIZZINESS; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HEART PROTECTION; HUMAN; MALAISE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VEIN DILATATION;

EID: 29144527442     PISSN: 14229528     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089603     Document Type: Review

References (92)

1. Abrams J: Nitroglycerin and long-acting nitrates in clinical practice. Am J Med 1983;74:85-94.
2. Kaski JC, Plaza LR, Meran DO, Araujo L, Chierchia S, Maseri A: Improved coronary supply: prevailing mechanism of action of nitrates in chronic stable angina. Am Heart J 1985;110:238-245.
3. Kannel WB, Feinleib M: Natural history of angina pectoris in the Framingham study. Prognosis and survival. Am J Cardiol 1972;29:154-163.
4. Rouleau JL, Talajic M, Sussex B, Potvin L, Warnica W, Davies RF, Gardner M, Stewart D, Plante S, Dupuis R, Lauzon C, Ferguson J, Mikes E, Balnozan V, Savard P: Myocardial infarction patients in the 1990s - Their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) Study. J Am Coll Cardiol 1996;27:1119-1127.
5. Taira N: Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates: an overview. J Cardiovasc Pharmacol 1987;10(suppl 8):S1-S9.
6. Kreye VAW, Lenz T, Pfrunder D: Mode of action of potassium channel openers in vascular smooth muscle. Rev Contemp Pharmacother 1993;4:185-198.
7. Berdeaux A, Drieu la Rochelle C, Richard V, Giudicelli JF: Differential effects of nitrovasodilators, K(+)-channel openers, and nicorandil on large and small coronary arteries in conscious dogs. J Cardiovasc Pharmacol 1992;20(suppl 3):S17-S21.
8. Escande D, Henry P: Potassium channels as pharmacological targets in cardiovascular medicine. Eur Heart J 1993;14(suppl B):2-9.
9. Tamargo J, Caballero R, Gomez R, Valenzuela C, Delpon E: Pharmacology of cardiac potassium channels. Cardiovasc Res 2004;62:9-33.
10. Daut J, Klieber HG, Cyrys S, Noack T: KATP channels and basal coronary vascular tone. Cardiovasc Res 1994;28:811-817.
11. Riccioppo Neto F, Mesquita Junior O, Olivera GB: Antiarrhythmic and electrophysiological effects of the novel KATP channel opener, rilmakalim, in rabbit cardiac cells. Gen Pharmacol 1997;29:201-205.
12. Garlid KD, Paucek P: Mitochondrial potassium transport: the K(+) cycle. Biochim Biophys Acta 2003;1606:23-41.
13. Halestrap AP, Clarke SJ, Javadov SA: Mitochondrial permeability transition pore opening during myocardial reperfusion - A target for cardioprotection. Cardiovasc Res 2004;61:372-385.
14. Baumbach A, Braun U, Doring G, Haase KK, Voelker W, Karsch KR: Double-blind comparison of the acute effects of two relevant doses of oral nicorandil on central hemodynamics, left ventricular function, and myocardial contractility. Cardiovasc Drugs Ther 1995;9(suppl 2):213-220.
15. Knight C, Purcell H, Fox K: Potassium channel openers: clinical applications in ischemic heart disease - Overview of clinical efficacy of nicorandil. Cardiovasc Drugs Ther 1995;9(suppl 2):229-236.
16. Yokota M, Horisawa T, Iwase M, Miyahara T, Yoshida J, Kamihara S, Noda S, Tsunekawa A, Koide M, Tsuzuki M, et al: Effects of a new vasodilator, nicorandil, on exercise-induced impairment of left ventricular function in patients with old myocardial infarction. J Cardiovasc Pharmacol 1987;10(suppl 8):S116-S122.
17. Silke B, Verma SP, Ali MS, Goldhammer E, Taylor SH: Effects of nicorandil on left ventricular hemodynamics and volume at rest and during exercise-induced angina pectoris. Am J Cardiol 1989;63:49J-55J.
18. Tsutamoto T, Kinoshita M, Nakae I, Maeda Y, Wada A, Yabe T, Horie H: Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure. Am Heart J 1994;127:866-873.
19. O'Rourke ST: KATP channel activation mediates nicorandil-induced relaxation of nitrate-tolerant coronary arteries. J Cardiovasc Pharmacol 1996;27:831-837.
20. Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136.
21. Yellon DM, Downey JM: Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003;83:1113-1151.
22. Gross GJ, Auchampach JA: Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992;70:223-233.
23. Van Winkle DM, Chien GL, Wolff RA, Soifer BE, Kuzume K, Davis RF: Cardioprotection provided by adenosine receptor activation is abolished by blockade of the KATP channel. Am J Physiol 1994;266:H829-H839.
24. Markham A, Plosker GL, Goa KL: Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs 2000;60:955-974.
25. + channels and myocardial preconditioning. Circ Res 1999;84:973-979.
26. + channels. Possible mechanism of cardioprotection. Circ Res 1997;81:1072-1082.
27. Liu Y, Sato T, O'Rourke B, Marban E: Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation 1998;97:2463-2469.
28. Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, Hori M, Kamada T, Tada M: Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 1993;72:1293-1299.
29. Marber MS, Latchman DS, Walker JM, Yellon DM: Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 1993;88:1264-1272.
30. Baxter GF, Goma FM, Yellon DM: Characterisation of the infarct-limiting effect of delayed preconditioning: timecourse and dose-dependency studies in rabbit myocardium. Basic Res Cardiol 1997;92:159-167.
31. Vegh A, Komori S, Szekeres L, Parratt JR: Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats. Cardiovasc Res 1992;26:487-495.
32. Bolli R, Bhatti ZA, Tang XL, Qiu Y, Zhang Q, Guo Y, Jadoon AK: Evidence that late preconditioning against myocardial stunning in conscious rabbits is triggered by the generation of nitric oxide. Circ Res 1997;81:42-52.
33. Sun JZ, Tang XL, Knowlton AA, Park SW, Qiu Y, Bolli R: Late preconditioning against myocardial stunning. An endogenous protective mechanism that confers resistance to postischemic dysfunction 24 h after brief ischemia in conscious pigs. J Clin Invest 1995;95:388-403.
34. Lee TM, Su SF, Chou TF, Lee YT, Tsai CH: Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty. Circulation 2002;105:334-340.
35. Lu EX, Chen SX, Hu TH, Xui LM, Yuan MD: Preconditioning enhances myocardial protection in patients undergoing open heart surgery. Thorac Cardiovasc Surg 1998;46:28-32.
36. Bahr R, Christenson R, Farin H, Hand M, Long JM: Prodromal symptoms of acute myocardial infarction: overview of evidence. Md Med 2001;(suppl):49-59.
37. Fukuzawa S, Ozawa S, Inagaki M, Shimada K, Sugioka J, Tateno K, Ueda M: Nicorandil affords cardioprotection in patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty: assessment with thallium-201/iodine-123 BMIPP dual SPECT. J Nucl Cardiol 2000;7:447-453.
38. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr: Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33:119-124.
39. Simpson D, Wellington K: Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients. Drugs 2004;64:1941-1955.
40. Frydman A: Pharmacokinetic profile of nicorandil in humans: an overview. J Cardiovasc Pharmacol 1992;20(suppl 3):S34-S44.
41. Frampton J, Buckley MM, Fitton A: Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs 1992;44:625-655.
42. The IONA Study Group: Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269-1275.
43. Roland E: Safety profile of an anti-anginal agent with potassium channel opening activity: an overview. Eur Heart J 1993;14(suppl B):48-52.
44. Witchitz S, Darmon JY: Nicorandil safety in the long-term treatment of coronary heart disease. Cardiovasc Drugs Ther 1995;9(suppl 2):237-243.
45. Dunn N, Freemantle S, Pearce G, Wilton LV, Mann RD: Safety profile of nicorandil - Prescription-event monitoring (PEM) study. Pharmacoepidemiol Drug Saf 1999;8:197-205.
46. Cribier B, Marquart-Elbaz C, Lipsker D, Alt M, Grosshans E: Chronic buccal ulceration induced by nicorandil. Br J Dermatol 1998;138:372-373.
47. Desruelles F, Bahadoran P, Lacour JP, Perrin C, Santini J, Ortonne JP: Giant oral aphthous ulcers induced by nicorandil. Br J Dermatol 1998;138:712-713.
48. Shotts RH, Scully C, Avery CM, Porter SR: Nicorandil-induced severe oral ulceration: a newly recognized drug reaction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;87:706-707.
49. Watson A, Al-Ozairi O, Fraser A, Loudon M, O'Kelly T: Nicorandil associated anal ulceration. Lancet 2002;360:546-547.
50. Vella M, Molloy RG: Nicorandil-associated anal ulceration. Lancet 2002;360:1979.
51. Passeron T, Lacour JP, Mantoux F, Fabiani P, Dubois D, Ortonne JP: Chronic anal ulceration due to nicorandil. Br J Dermatol 2004;150:394-396.
52. Doring G: Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 1992;20(suppl 3):S74-S81.
53. Hughes LO, Rose EL, Lahiri A, Raftery EB: Comparison of nicorandil and atenolol in stable angina pectoris. Am J Cardiol 1990;66:679-682.
54. Ciampricotti R, Schotborgh CE, de Kam PJ, van Herwaarden RH: A comparison of nicorandil with isosorbide mononitrate in elderly patients with stable coronary heart disease: the SNAPE study. Am Heart J 2000;139:939-943.
55. Ulvenstam G, Diderholm E, Frithz G, Gudbrandsson T, Hedback B, Hoglund C, Moelstad P, Perk J, Sverrisson JT: Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. J Cardiovasc Pharmacol 1992;20(suppl 3):S67-S73.
56. Meeter K, Kelder JC, Tijssen JG, Bucx JJ, Henneman JA, Kerker JP, Hugenkoltz PG: Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study. J Cardiovasc Pharmacol 1992;20(suppl 3):S59-S66.
57. SWAN Study group: Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study. J Clin Basic Cardiol 1999;2:213-217.
58. Di Somma S, Liguori V, Petitto M, Carotenuto A, Bokor D, de Divitiis O, de Divitiis M: A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther 1993;7:119-123.
59. Guermonprez JL, Blin P, Peterlongo F: A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J 1993;14(suppl B):30-34.
60. Impact of nicorandil in angina: subgroup analyses. Heart 2004;90:1427-1430.
61. Tang XL, Xuan YT, Zhu Y, Shirk G, Bolli R: Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits. Am J Physiol Heart Circ Physiol 2004;286:H1273-H1280.
62. Mizuo N, Iwao I, Yoshiya M, Yoshiaki S, Susumu N, Nehiro K, Nobuyuki K, Kouichi T, Yoshiaki M, Issei K: Comparison between nicorandil and magnesium as an adjunct cardioprotective agent to percutaneous coronary intervention in acute anterior myocardial infarction. Circ J 2004;68:192-197.
63. Sugimoto K, Ito H, Iwakura K, Ikushima M, Kato A, Kimura R, Tanaka K, Masuyama T, Ogihara T, Kawano S, Fujii K: Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. Circ J 2003;67:295-300.
64. Ueda H, Nakayama Y, Tsumura K, Yoshimaru K, Hayashi T, Yoshikawa J: Intravenous nicorandil can reduce the occurrence of ventricular fibrillation and QT dispersion in patients with successful coronary angioplasty in acute myocardial infarction. Can J Cardiol 2004;20:625-629.
65. Kloner RA: Does reperfusion injury exist in humans? J Am Coll Cardiol 1993;21:537-545.
66. Pieper GM, Gross GJ: Anti-free-radical and neutrophil-modulating properties of the nitrovasodilator, nicorandil. Cardiovasc Drugs Ther 1992;6:225-232.
67. Yasu T, Ikeda N, Ishizuka N, Matsuda E, Kawakami M, Kuroki M, Imai N, Ueba H, Fukuda S, Schmid-Schonbein GW, Saito M: Nicorandil and leukocyte activation. J Cardiovasc Pharmacol 2002;40:684-692.
68. Ono H, Osanai T, Ishizaka H, Hanada H, Kamada T, Onodera H, Fujita N, Sasaki S, Matsunaga T, Okumura K: Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J 2004;148:E15.
69. + channel opener nicorandil. Eur Heart J 2003;24:1296-1303.
70. Sakata Y, Kodama K, Komamura K, Lim YJ, Ishikura F, Hirayama A, Kitakaze M, Masuyama T, Hori M: Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction. Am Heart J 1997;133:616-621.
71. Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, Hori M, Higashino Y, Fujii K, Minamino T: Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999;33:654-660.
72. Cannon RO 3rd, Dilsizian V, O'Gara PT, Udelson JE, Schenke WH, Quyyumi A, Fananapazir L, Bonow RO: Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation 1991;83:1660-1667.
73. Takeichi Y, Yokota M, Iwase M, Izawa H, Nishizawa T, Ishiki R, Somura F, Nagata K, Isobe S, Noda A: Biphasic changes in left ventricular end-diastolic pressure during dynamic exercise in patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2001;38:335-343.
74. Young MA, Knight DR, Vatner SF: Autonomic control of large coronary arteries and resistance vessels. Prog Cardiovasc Dis 1987;30:211-234.
75. Izawa H, Iwase M, Takeichi Y, Somura F, Nagata K, Nishizawa T, Noda A, Murohara T, Yokota M: Effect of nicorandil on left ventricular end-diastolic pressure during exercise in patients with hypertrophic cardiomyopathy. Eur Heart J 2003;24:1340-1348.
76. Solal AC, Jaeger P, Bouthier J, Juliard JM, Dahan M, Gourgon R: Hemodynamic action of nicorandil in chronic congestive heart failure. Am J Cardiol 1989;63:44J-48J.
77. Tsutamoto T, Kinoshita M, Hisanaga T, Maeda Y, Maeda K, Wada A, Fukai D, Yoshida S: Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure. Am J Cardiol 1995;75:1162-1165.
78. Saeed M, Watzinger N, Krombach GA, Lund GK, Wendland MF, Chujo M, Higgins CB: Left ventricular remodelling after infarction: sequential MR imaging with oral nicorandil therapy in rat model. Radiology 2002;224:830-837.
79. Drexler H, Hayoz D, Munzel T, Hornig B, Just H, Brunner HR, Zelis R: Endothelial function in chronic congestive heart failure. Am J Cardiol 1992;69:1596-1601.
80. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhoy KN: Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998;31:1352-1356.
81. Belch JJ, Bridges AB, Scott N, Chopra M: Oxygen free radicals and congestive heart failure. Br Heart J 1991;65:245-248.
82. Dixon LJ, Morgan DR, Hughes SM, McGrath LT, El-Sherbeeny NA, Plumb RD, Devine A, Leahey W, Johnston GD, McVeigh GE: Functional consequences of endothelial nitric oxide synthase uncoupling in congestive cardiac failure. Circulation 2003;107:1725-1728.
83. Prabhu SD: Nitric oxide protects against pathological ventricular remodelling: reconsideration of the role of NO in the failing heart. Circ Res 2004;94:1155-1157.
84. Janssens S, Pokreisz P, Schoonjans L, Pellens M, Vermeersch P, Tjwa M, Jans P, Scherrer-Crosbie M, Picard MH, Szelid Z, Gillijns H, Van de Werf F, Collen D, Bloch KD: Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 2004;94:1256-1262.
85. Scherrer-Crosbie M, Ullrich R, Bloch KD, Nakajima H, Nasseri B, Aretz HT, Lindsey ML, Vancon AC, Huang PL, Lee RT, Zapol WM, Picard MH: Endothelial nitric oxide synthase limits left ventricular remodelling after myocardial infarction in mice. Circulation 2001;104:1286-1291.
86. Drexler H: Nitric oxide synthases in the failing human heart: a doubled-edged sword? Circulation 1999;99:2972-2975.
87. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, et al: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-1552.
88. Ignarro LJ, Napoli C, Loscalzo J: Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 2002;90:21-28.
89. Bauer JA, Fung HL: Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 1991;84:35-39.
90. Munzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA, Freeman BA, Harrison DG: Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 1996;98:1465-1470.
91. Ozcan C, Bienengraeber M, Dzeja PP, Terzic A: Potassium channel openers protect cardiac mitochondria by attenuating oxidant stress at reoxygenation. Am J Physiol Heart Circ Physiol 2002;282:H531-H539.
92. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-2057.